Aeglea BioTherapeutics appoints Jim Kastenmayer as general counsel
Aeglea Biotherapeutics, a clinical-stage biotechnology, announced the appointment of Jim Kastenmayer (pictured) as general counsel.
Kastenmayer’s most recent appointment was at Viela Bio, where he served as general counsel for a little over a year. Prior to that, Kastenmayer was a part of the AstraZeneca global legal team. He joined AstraZeneca in 2012 as senior patent director and rose through the legal department ranks in various roles before he was named global legal director for the oncology unit. Earlier in his career, Kastenmayer was a patent attorney with Finnegan Henderson Farabow Garrett & Dunner law firm. He then moved to Medimmune biotechnology company as intellectual property corporate counsel.
Aeglea Biotherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options.